Evidence map›Paper›PMID 38005872›Full record

ArticleViruses2023

Genomic and Epidemiologic Surveillance of SARS-CoV-2 in the Pandemic Period: Sequencing Network of the Lazio Region, Italy.

Martina Rueca, Giulia Berno, Alessandro Agresta, Martina Spaziante, Cesare Ernesto Maria Gruber, Lavinia Fabeni, Emanuela Giombini, Ornella Butera, Alessandra Barca, Paola Scognamiglio and 5 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Martina RuecaNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.ORCID 0000-0001-5162-046X
Giulia BernoNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.
Alessandro AgrestaNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.
Martina SpazianteNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.
Cesare Ernesto Maria GruberNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.ORCID 0000-0002-8831-3380
Lavinia FabeniNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.
Emanuela GiombiniNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.ORCID 0000-0003-2237-9755
Ornella ButeraNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.
Alessandra BarcaDirezione Regionale Salute E Integrazione Sociosanitaria, Area Promozione Della Salute E Prevenzione-Regione Lazio, 00145 Rome, Italy.
Paola ScognamiglioNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.
Enrico GirardiNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.ORCID 0000-0001-8182-5896
Fabrizio MaggiNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.ORCID 0000-0001-7489-5271
Maria Beatrice ValliNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.
Francesco VairoNational Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.
Sars-CoV-Lazio Genomic Surveillance Study Group
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITRegione Lazio

Funding

Ministero della Salute 5M-2020-23682104Ministero della Salute Ricerca Corrente - Linea 1
6 · The paper itself

Abstract

Since the beginning of the COVID-19 pandemic, large-scale genomic sequencing has immediately pointed out that SARS-CoV-2 has rapidly mutated during the course of the pandemic, resulting in the emergence of variants with a public health impact. In this context, strictly monitoring the circulating strains via NGS has proven to be crucial for the early identification of new emerging variants and the study of the genomic evolution and transmission of SARS-CoV-2. Following national and international guidelines, the Lazio region has created a sequencing laboratory network (WGSnet-Lazio) that works in synergy with the reference center for epidemiological surveillance (SERESMI) to monitor the circulation of SARS-CoV-2. Sequencing was carried out with the aims of characterizing outbreak transmission dynamics, performing the genomic analysis of viruses infecting specific categories of patients (i.e., immune-depressed, travelers, and people with severe symptoms) and randomly monitoring variant circulation. Here we report data emerging from sequencing activities carried out by WGSnet-Lazio (from February 2020 to October 2022) linked with epidemiological data to correlate the circulation of variants with the clinical and demographic characteristics of patients. The model of the sequencing network developed in the Lazio region proved to be a useful tool for SARS-CoV-2 surveillance and to support public health measures for epidemic containment.

Indexed as

COVID-19SARS-CoV-2Epidemiological MonitoringGenomicsHumansItalyPandemicsepidemiologygenomic surveillanceNext Generation SequencingSARS-CoV-2SARS-CoV-2 variantssequencing network

Identifiers

PMID38005872
PMCPMC10674723
OpenAlexW4388071558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.